| Part One: Foundations of Bio-Medical Ethics and Modern "Bio-Politics" |
| 1 |
Section One: Introduction: Bio-Medical Ethics and Bio-Politics: From Clinical Practice and Medical Research to Crisis of Medical Humanitarianism in the Field (PDF) |
| 2 |
Section Two: Principles of Ethical Medical Practice and Research: Autonomy, Justice, Beneficence, and Nonmaleficience (PDF)
What is Bio-Medical Ethics? |
| 3-4 |
Section Three: Competing Discourses on Bioethics and Bio-Medical Practice - Anthropology, Feminism, Theology, and Law (PDF) |
| 5-7 |
Section Four: The Creation of Doctors and the Clinical Gaze or "Whose Body Is It, Anyway?" (PDF 1) (PDF 2) (PDF 3) |
| 8-9 |
Section Five: Ethical Issues in the Practice of Medicine: Confidentiality and Disclosure; Patient Autonomy and Informed Consent (PDF 1) (PDF 2) |
| 10-11 |
Section Six: Dilemmas of Public Health Practice: The Limits of Resources and its Allocation (PDF 1) (PDF 2) |
| Part Two: Medical Technologies, the Body and the State |
| 12-13 |
Section Seven: Medical Research and Ethical Medical Experimentation - from Eugenics to Anti-Retroviral Drug Trials (PDF 1) (PDF 2) |
| 14-15 |
Section Eight: Race, Contraception and Family Planning: Contemporary Eugenics? (PDF 1) (PDF 2) |
| Part Three: Globalizing Bioethics - The Politics of Reproduction |
| 16-17 |
Section Nine: The Politics of Gender, Reproductive Technologies and Family Planning across Cultures (PDF 1) (PDF 2) |
| 18 |
Section Ten: Infertility, Assisted Reproduction, Kinship, and Citizenship across Cultures (PDF) |
| 19-20 |
Section Eleven: State Politics of Human Genetic Engineering, Stem Cell Research, Cloning, and "Surplus Embryos" (PDF 1) (PDF 2)
Lecture 20
Guest Speaker: Dr. James Sherley, MIT Assoc. Professor of Biological Engineering |
| Part Four: Playing God? Life, Death, Bodies, and Spirits |
| 21-24 |
Section Twelve: Organ Transplantation, End of Life Issues, and Death across Cultures (PDF 1) (PDF 2) (PDF 3) (PDF 4) |
| Part Five: Human Rights, Infectious Disease, and the Global Medical Commons |
| 25-26 |
Section Thirteen: Clinical Dilemmas, Public Health, and Global Pharmaceuticals (PDF 1) (PDF 2) |